MetaCap

Madrigal Pharmaceuticals (MDGL) vs Rhythm Pharmaceuticals (RYTM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Rhythm Pharmaceuticals (RYTM) has outperformed Madrigal Pharmaceuticals (MDGL) over the past year, gaining 10.4% versus a loss of 30.8%. Over five years, RYTM leads with a +1116.0% price change compared with +362.0% for MDGL. Madrigal Pharmaceuticals is the larger company by market cap ($8.81 billion vs $7.79 billion), about 1.1 times the size.

Madrigal Pharmaceuticals converts more of its revenue into profit, with a net margin of -30.1% versus -103.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MDGL-30.82%RYTM+10.44%
+19%-7%-33%
Nov 21, 20251 yearNov 20, 2026
MDGL+360.07%RYTM+990.87%
+1077%+477%-123%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MDGL versus RYTM key metrics
MetricMDGLRYTM
Share price$379.10$112.36
Market cap$8.81B$7.79B
1-day change-4.45%-3.80%
YTD return-34.90%+4.97%
1-year return-30.82%+10.44%
5-year return+361.98%+1116.02%
Forward P/E36.52—
EPS (TTM)$-5.85$-2.91
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$958.40M$189.76M
Revenue growth (YoY)+432.05%+45.83%
Net income (latest FY)$-288.28M$-196.54M
Gross margin—89.73%
Operating margin-31.31%-101.19%
Net margin-30.08%-103.57%
52-week high$615.00$122.20
52-week low$353.54$74.50
Distance from 52-week high-38.36%-8.05%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+81.69%+24.71%
Average volume370.07K1.10M
Shares outstanding23.23M69.33M
Employees915414
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RYTM has outperformed MDGL by 41.3 percentage points over the past year.
  • Madrigal Pharmaceuticals is more profitable, keeping -30.1 cents of every revenue dollar as net income versus -103.6 cents for Rhythm Pharmaceuticals.
  • Madrigal Pharmaceuticals grew revenue faster in its latest fiscal year (+432.05% vs +45.83%).

About Madrigal Pharmaceuticals

MDGL stock →

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.

Health Care · Biotechnology: Pharmaceutical Preparations · 915 employees

About Rhythm Pharmaceuticals

RYTM stock →

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.

Health Care · Biotechnology: Pharmaceutical Preparations · 414 employees

MDGL vs RYTM FAQ

Which is bigger, Madrigal Pharmaceuticals or Rhythm Pharmaceuticals?

Madrigal Pharmaceuticals (MDGL) is larger, with a market capitalization of $8.81B compared with $7.79B for Rhythm Pharmaceuticals (RYTM).

Which stock has performed better over the past year, MDGL or RYTM?

RYTM returned +10.44% over the past 12 months, compared with -30.82% for MDGL (price return, excluding dividends). Past performance does not predict future results.

Are Madrigal Pharmaceuticals and Rhythm Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons